Idebenone: A guide to its use in Alzheimers disease, other age-related cognitive disorders and Friedreichs ataxia
Deary I., Corley J., Gow A., Adkins J., Noble S., Gillis J., Benfield P., McTavish D., Tsou A., Friedman L., Wilson R., Boni J., Maugeri A., Zingali G., Bergamasco B., Scarzella L., La Commare P., Senin U., Parnetti L., Barbagallo-Sangiorgi G., Weyer G., Babej-Dlle R., Hadler D., Weyer G., Erzigkeit H., Hadler D., Voronkova K., Meleshkov M., Guztmann H., Khl K., Hadler D., Bergamasco B., Villardita C., Coppi R., Marigliano V., Abate G., Barbagallo-Sangiorgi G., Lingetti M., Porfido F., Ciarimboli M., Nappi G., Bono G., Merlo P., Kadota I., Matsuoka M., Shirakawa S., Takauchi S., Miyoshi K., Di Prospero N., Baker A., Jeffries N., Mariotti C., Solari A., Torta D., Artuch R., Aracil A., Mas A., Buyse G., Mertens L., Di Salvo G., Hausse A., Aggoun Y., Bonnet D., Pineda M., Arpa J., Montero R., Riba P., Pousset F., Tanguy M., Rinaldi C., Tucci T., Maione S., Sival D., De Marchie Sarvass C., Brouwer O., Trujillo-Martn M., Serrano-Aguilar P., Monton-Alvarez F.
Oral idebenone is a valuable, well tolerated and safe option for improving cognitive function and other clinical symptoms in patients with Alzheimer's disease and other age-related cognitive disorders. It has also shown some promising results in delaying the progression of neurological symptoms and cardiac hypertrophy in patients with Friedreich's ataxia. © 2010 Adis Data Information BV. All rights reserved.